English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/125806
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

IGF-1 in autosomal dominant cerebellar ataxia - open-label trial

AutorSanz-Gallego, Irene; Rodríguez de Rivera, Francisco J.; Pulido, Irene; Torres Alemán, Ignacio ; Arpa, Javier
Palabras claveADCA
IGF-1 therapy
Fecha de publicación2-oct-2014
EditorBioMed Central
CitaciónCerebellum & Ataxias 1(1): 13 (2014)
Resumen[Background] The objective of this clinical open-label trial was to test the safety, tolerability and efficacy of IGF-1 therapy for autosomal dominant cerebellar ataxia (ADCA) patients.
[Results] A total of 19 molecularly confirmed patients with SCA3, 1 patient with SCA6 and 6 patients with SCA7 completed our study. They were 8 females and 18 males, 28 to 74 years of age (average ± SD: 49.3 ± 14.1). Patients were treated with IGF-1 therapy with a dosage of 50 μg/kg twice a day for 12 months. The efficacy of this therapy was assessed by change from baseline on the scale for the assessment and rating of ataxia (SARA). Ten patients, consecutively selected, continued their assigned dosages in a second year open-label extension trial. A statistically significant improvement in SARA scores was observed for patients with SCA3, patients with SCA7 and all patients grouped together after the first year of IGF-1 therapy, while a stabilization of the disease was confirmed during the second year (extension study). The single patient with SCA6 showed 3 improvement points in SARA score after 3 four-month periods of IGF-1 therapy when compared with baseline measurements. Our data indicate that IGF-1 is safe and well tolerated in general.
[Conclusions] Our data, in comparison with results from previous cohorts, indicate a trend for IGF-1 treatment to stabilize the disease progression for patients with SCA, indicating that IGF-1 therapy is able to decrease the progressivity of ADCA.
Versión del editorhttp://dx.doi.org/10.1186/s40673-014-0013-8
Aparece en las colecciones: (IC) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
40673_2014_Article_13.pdf1,02 MBAdobe PDFVista previa
Mostrar el registro completo

Artículos relacionados:

NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.